Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Leukemia, Myeloid, Acute 17Leukemia, Myelomonocytic, Acute 11Leukemia, Monocytic, Acute 11Leukemia, Megakaryoblastic, Acute 11Leukemia, Erythroblastic, Acute 11Breast Neoplasms 11Congenital Abnormalities 9Leukemia 7Glioblastoma 7Recurrence 6Pancreatic Neoplasms 6Multiple Myeloma 5Leukemia, Myelomonocytic, Chronic 5Leukemia, Eosinophilic, Acute 5Leukemia, Basophilic, Acute 5Gliosarcoma 5Carcinoma, Non-Small-Cell Lung 5Anemia, Refractory, with Excess of Blasts 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Non-Hodgkin 4Lymphoma 4Breast Neoplasms, Male 4Brain Neoplasms 4Blast Crisis 4Urinary Bladder Neoplasms 3Unspecified Adult Solid Tumor, Protocol Specific 3Thyroid Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Neuroblastoma 3Melanoma 3

Interventions

Temozolomide 3gadobenic acid 2XENP 1595 2Trastuzumab 2Sodium Chloride 2Dexmedetomidine 2Cancer Vaccines 2Adjuvants, Immunologic 2veliparib 1tucatinib 1tipifarnib 1sagopilone 1pembrolizumab 1interferon gamma-1b 1glutathione pegylated liposomal doxorubicin 1gadoteridol 1elacestrant 1abemaciclib 1Tissue Banks 1Saline Solution 1Rituximab 1Radiotherapy 1Radiation 1RAD1901 1Oncolytic Virotherapy 1Interferon-gamma 1Immunotherapy 1Dasatinib 1Craniotomy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Central Nervous System Diseases × tipifarnib × Clear all
NCT00050986 2020-09-22

Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma Multiforme

M.D. Anderson Cancer Center

Phase 1/2 Completed
55 enrolled 6 charts
CNS

Brain Neoplasms, Central Nervous System Diseases, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡